TMS Co Ltd
TSE:4891
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
151
337
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one TMS Co Ltd stock under the Base Case scenario is 101.16 JPY. Compared to the current market price of 225 JPY, TMS Co Ltd is Overvalued by 55%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
TMS Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for TMS Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
TMS Co Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
TMS Co Ltd
Balance Sheet Decomposition
TMS Co Ltd
Current Assets | 3.1B |
Cash & Short-Term Investments | 3B |
Receivables | 27.7m |
Other Current Assets | 47.7m |
Non-Current Assets | 3.2m |
Other Non-Current Assets | 3.2m |
Current Liabilities | 99.1m |
Accrued Liabilities | 61.8m |
Other Current Liabilities | 37.3m |
Non-Current Liabilities | 1k |
Other Non-Current Liabilities | 1k |
Earnings Waterfall
TMS Co Ltd
Revenue
|
0
JPY
|
Operating Expenses
|
-1.1B
JPY
|
Operating Income
|
-1.1B
JPY
|
Other Expenses
|
-44.9m
JPY
|
Net Income
|
-1.1B
JPY
|
Free Cash Flow Analysis
TMS Co Ltd
JPY | |
Free Cash Flow | JPY |
Profitability Score
Profitability Due Diligence
TMS Co Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
TMS Co Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
TMS Co Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
TMS Co Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
TMS Co Ltd
According to Wall Street analysts, the average 1-year price target for TMS Co Ltd is 775.2 JPY with a low forecast of 767.6 JPY and a high forecast of 798 JPY.
Dividends
Current shareholder yield for TMS Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
TMS Co., Ltd. engages in the research and development of pharmaceutical products and medical devices. The company is headquartered in Fuchu-Shi, Tokyo-To and currently employs 8 full-time employees. The company went IPO on 2022-11-22. The firm conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.
Contact
IPO
Employees
Officers
The intrinsic value of one TMS Co Ltd stock under the Base Case scenario is 101.16 JPY.
Compared to the current market price of 225 JPY, TMS Co Ltd is Overvalued by 55%.